Fatigue

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	60

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

trials per page:

Showing 1 to 10 of 60 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05378100 (ClinicalTrials.gov)	January 1, 2023	12/5/2022	Ketamine for Multiple Sclerosis Fatigue	Low-Dose Ketamine Infusion for the Treatment of Multiple Sclerosis Fatigue (INKLING-MS)	Multiple Sclerosis Fatigue	Drug: Ketamine;Drug: Midazolam	Johns Hopkins University	United States Department of Defense	Recruiting	18 Years	65 Years	All	110	Phase 2	United States
2	NCT04880577 (ClinicalTrials.gov)	September 15, 2022	30/4/2021	Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple ...	Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple ...	Multiple Sclerosis, Relapsing-Remitting;Fatigue	Drug: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY];Drug: Placebo	Massachusetts General Hospital	Gilead Sciences	Withdrawn	18 Years	N/A	All	0	Phase 2	United States
3	EUCTR2021-004868-95-ES (EUCTR)	26/05/2022	22/12/2021	AMANTADINE AND TRANSCRANIAL MAGNETIC STIMULATION FOR TREATING FATIGUE IN MULTIPLE SCLEROSIS	AMANTADINE AND TRANSCRANIAL MAGNETIC STIMULATION FOR TREATING FATIGUEIN MULTIPLE SCLEROSIS: PHASE II ...	Fatigue in multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Amantadine Level Product Name: Amantadine INN or Proposed INN: INN Other descriptive name: ...	Fundación para la Inv. Biomédica Hospital Clínico San Carlos	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	144	Phase 4	Spain
4	NCT05319093 (ClinicalTrials.gov)	April 2022	1/4/2022	Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients	Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients	Fatigue;Multiple Sclerosis	Drug: Ozanimod	Brigham and Women's Hospital	Bristol-Myers Squibb	Not yet recruiting	18 Years	N/A	All	40		NULL
5	NCT04764383 (ClinicalTrials.gov)	January 1, 2022	18/2/2021	Histaminergic Basis of Fatigue in Multiple Sclerosis	Histaminergic Basis of Fatigue in Multiple Sclerosis	Multiple Sclerosis	Drug: L-Histidine;Drug: Placebo;Drug: Lodosyn	University of Miami	NULL	Withdrawn	18 Years	60 Years	All	0	Phase 2	United States
6	NCT03807973 (ClinicalTrials.gov)	October 5, 2021	14/1/2019	Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Z ...	Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Z ...	Fibromyalgia;Chronic Fatigue Syndrome;Multiple Sclerosis;Healthy	Drug: [Zr-89]Oxine-labeled leukocytes PET/MRI	University of Alabama at Birmingham	NULL	Recruiting	18 Years	65 Years	All	120	Phase 1	United States
7	NCT04885894 (ClinicalTrials.gov)	September 2021	11/5/2021	An Examination of Cognitive Fatigue Using Functional Neuroimaging	An Examination of Cognitive Fatigue Using Functional Neuroimaging	Multiple Sclerosis, Relapsing-Remitting	Drug: Zeposia	Kessler Foundation	Celgene;Hackensack Meridian Health;St. Barnabas Medical Center	Not yet recruiting	18 Years	64 Years	All	60		United States
8	NCT05730738 (ClinicalTrials.gov)	June 1, 2021	5/12/2021	Dalfampridine in Egyptian Patients With Multiple Sclerosis	Effect of Dalfampridine on Gait Impairment, Cognition and Fatiguein Egyptian Patients With Multiple ...	Multiple Sclerosis	Drug: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release;Drug: Placebo	Ain Shams University	NULL	Recruiting	18 Years	N/A	All	100	N/A	Egypt
9	NCT04448977 (ClinicalTrials.gov)	May 6, 2021	15/6/2020	Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI	A Biomarker for Cognitive Fatigue Using Functional Imaging in MS	Multiple Sclerosis, Relapsing-Remitting	Drug: Ocrevus	Kessler Foundation	Hackensack Meridian Health	Recruiting	18 Years	64 Years	All	60		United States
10	NCT04565431 (ClinicalTrials.gov)	March 19, 2021	25/8/2020	Examining Effects of Tysabri on Cognitive Fatigue Using fMRI	Biomarker for Cognitive Fatigue Using Functional Imaging in Multiple Sclerosis	Multiple Sclerosis, Relapsing-Remitting	Drug: Tysabri	Kessler Foundation	St. Barnabas Medical Center	Recruiting	18 Years	64 Years	All	25		United States

First Previous1 2 3 4 5 6Next Last